Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents

In this: publication
By this: publisher
In this Subject: Pharmacology
By this author: Laird A.D. ;&nbsp; Cherrington J.M.

Authors: Laird A.D.; Cherrington J.M.

Source: Expert Opinion on Investigational Drugs, Volume 12, Number 1, 1 January 2003 , pp. 51-64(14)

Buy & download fulltext article:

Price: $99.00 plus tax (Refund Policy)

Abstract:

Numerous small molecule synthetic tyrosine kinase inhibitors are in clinical development for the treatment of human cancers. These fall into three broad categories: inhibitors of the epidermal growth factor receptor tyrosine kinase family (e.g., Iressa™ and Tarceva™), inhibitors of the split kinase domain receptor tyrosine kinase subgroup (e.g., PTK787/ZK 222584 and SU11248) and inhibitors of tyrosine kinases from multiple subgroups (e.g., Gleevec™). In addition, agents targeting other tyrosine kinases implicated in cancer, such as Met, Tie-2 and Src, are in preclinical development. As experience is gained in the clinic, it has become clear that unleashing the full therapeutic potential of tyrosine kinase inhibitors will require patient preselection, better assays to guide dose selection, knowledge of mechanism-based side effects and ways to predict and overcome drug resistance.

Keywords: Bcr-Abl; cancer; EGFR; FGFR; Flt-3; HER2; inhibitor; KIT; leukaemia; maximum tolerated dose; Met; PDGFR; receptor; Src; Tie-2; tyrosine kinase; VEGFR